Treatment of recurrent intrahepatic cholangiocarcinoma

British Journal of Surgery

Volumn 99, Issue 12, 2012, Pages 1711-1717

  Sulpice, L ^a,c   Rayar, M ^a   Boucher, E ^b,c   Pracht, M ^b   Meunier, B ^a   Boudjema, K ^a,c  

^a UNIVERSITÉ DE RENNES 1   (France)

^b Centre de Lutte Contre Le Cancer Eugène Marquis   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; FEMALE; HUMAN; INTRAHEPATIC BILE DUCT; KAPLAN MEIER METHOD; LIVER TUMOR; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TUMOR RECURRENCE;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84868641908     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.8953     Document Type: Article

References (30)

1. Cho SY, Park SJ, Kim SH, Han SS, Kim YK, Lee KW, et al., Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol 2010; 17: 1823-1830.
2. Patel T,. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357.
3. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al., Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-820.
4. Lee GW, Kang JH, Kim HG, Lee JS, Lee JS, Jang JS,. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol 2006; 29: 127-131.
5. Feisthammel J, Schoppmeyer K, Mossner J, Schulze M, Caca K, Wiedmann M,. Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial. Am J Clin Oncol 2007; 30: 319-324.
6. Yamanaka N, Okamoto E, Ando T, Oriyama T, Fujimoto J, Furukawa K, et al., Clinicopathologic spectrum of resected extraductal mass-forming intrahepatic cholangiocarcinoma. Cancer 1995; 76: 2449-2456.
7. Lang H, Sotiropoulos GC, Frühauf NR, Dömland M, Paul A, Kind EM, et al., Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005; 241: 134-143.
8. Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, et al., Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000; 127: 498-505.
9. Ercolani G, Vetrone G, Grazi GL, Aramaki O, Cescon M, Ravaioli M, et al., Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg 2010; 252: 107-114.
10. Cherqui D, Tantawi B, Alon R, Piedbois P, Rahmouni A, Dhumeaux D, et al., Intrahepatic cholangiocarcinoma. Results of aggressive surgical management. Arch Surg 1995; 130: 1073-1078.
11. Liver Cancer Study Group of Japan. Classification of Primary Liver Cancer (1st edn). Kanehara: Tokyo, 2011.
12. Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D, et al., The '50-50 criteria' on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 2005; 242: 824-828.
13. Strasberg SM,. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 2005; 12: 351-355.
14. Salem R, Thurston KG,. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 2006; 17: 1571-1593.
15. Garin E, Rolland Y, Boucher E, Ardisson V, Laffont S, Boudjema K, et al., First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging 2010; 37: 453-461.
16. Yamamoto M, Ariizumi S,. Surgical outcomes of intrahepatic cholangiocarcinoma. Surg Today 2011; 41: 896-902.
17. Nakagawa T, Kamiyama T, Kurauchi N, Matsushita M, Nakanishi K, Kamachi H, et al., Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005; 29: 728-733.
18. Choi SB, Kim KS, Choi JY, Park SW, Choi JS, Lee WJ, et al., The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009; 16: 3048-3056.
19. Farges O, Fuks D, Boleslawski E, Le Treut YP, Castaing D, Laurent A, et al., Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg 2011; 254: 824-829.
20. Igami T, Ebata T, Yokoyama Y, Sugawara G, Takahashi Y, Nagino M,. Staging of peripheral-type intrahepatic cholangiocarcinoma: appraisal of the new TNM classification and its modifications. World J Surg 2011; 35: 2501-2509.
21. Uchiyama K, Yamamoto M, Yamaue H, Ariizumi S, Aoki T, Kokudo N, et al., Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2011; 18: 443-452.
22. Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, et al., Significance of repeated resection for recurrent intrahepatic cholangiocarcinoma. Hepatogastroenterology 2009; 56: 1-5.
23. Kitagawa D, Taketomi A, Aishima S, Kuroda Y, Gion T, Shirabe K, et al., Recurrence of intrahepatic cholangiocarcinoma nine years after surgical resection. Hepatogastroenterology 2008; 55: 1085-1088.
24. Kamphues C, Seehofer D, Eisele RM, Denecke T, Pratschke J, Neumann UP, et al., Recurrent intrahepatic cholangiocarcinoma: single-center experience using repeated hepatectomy and radiofrequency ablation. J Hepatobiliary Pancreat Sci 2010; 17: 509-515.
25. Herzer K, Müller S, Antoch G, Hilgard P,. Locoregional therapy for hepatocellular carcinoma: radioembolization with yttrium-90 microspheres. Minerva Gastroenterol Dietol 2011; 57: 287-298.
26. Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R,. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol 2011; 21: 294-302.
27. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al.,; European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-878.
28. Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, et al., Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008; 113: 2119-2128.
29. Saxena A, Bester L, Chua TC, Chu FC, Morris DL,. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; 17: 484-491.
30. Whitney R, Tatum C, Hahl M, Ellis S, Scoggins CR, McMasters K, et al., Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. J Surg Res 2011; 166: 236-240.